# The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome

> **NCT05667727** · PHASE4 · COMPLETED · sponsor: **Oman Medical Speciality Board** · enrollment: 30 (actual)

## Conditions studied

- Shortness of Breath
- Asthma in Children
- Epinephrine Causing Adverse Effects in Therapeutic Use
- Salbutamol Adverse Reaction

## Interventions

- **DRUG:** nebulized epinephrine
- **DRUG:** Salbutamol

## Key facts

- **NCT ID:** NCT05667727
- **Lead sponsor:** Oman Medical Speciality Board
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-15
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667727, "The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05667727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*